Tissue Factor Dependent Pathway and the Diagnosis of Pre-Eclampsia

ABSTRACT

Pre-eclampsia (P-EC) is a major contributor to perinatal and maternal morbidity and mortality worldwide. Its etiology and pathogenesis remains poorly understood, and differential diagnosis is problematic. During a normal pregnancy, coagulation activation is essential for physiological placental hemostasis, but women with P-EC tend to be more hypercoagulable than normal pregnant women. A common proposed mechanism for P-EC is utero-placental thrombosis. Indeed, multiple placental microthrombi are frequently observed in women with P-EC, and these may compromise placental perfusion and fetal development. This suggests that predisposing factors to thrombosis could contribute to the development of P-EC. Thus studying circulating hemostatic proteins may help elucidate some of the pathogenesis of P-EC and may provide a rational basis for its differential diagnosis and effective treatment. Preliminary studies by our group on third-trimester women suggest that raised circulating factor VII (FVII) is a selective marker for P-EC when women with P-EC were compared with healthy nonpregnant or normal pregnant women groups. Plasma FVII levels have shown good sensitivity and specificity for P-EC of 90% and 80%, respectively. However, significant comparable changes in the other tissue factor (TF)-dependent pathway factors (activated FVII), TF, and tissue factor pathway inhibitor were not observed. Thus we propose the use of plasma FVII as a potential marker of P-EC.

KEYWORDS

Coagulation - FVII - FVIIa - TF - TFPI - pre-eclampsia

REFERENCES

• 1 Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity: case-control study.  BMJ. 2001;  322 (7294) 1089-1093 discussion 1093-1094
• 2 National Institute for Health and Clinical Excellence .Antenatal Care: Routine Care for the Healthy Pregnant Woman. National Institute for Health and Clinical Excellence 2003
• 3 Villar J, Say L, Gülmezoglu A M et al.. Eclampsia and pre-eclampsia a worldwide health problem for 2000 years. In: Critchley H, MacLean A, Poston L, Walker J, eds. Pre-Eclampsia. London, United Kingdom: RCOG Press; 2003: 189-207
• 4 Harrison M J, Kushner K E, Benzies K, Kimak C, Jacobs P, Mitchell B F. In-home nursing care for women with high-risk pregnancies: outcomes and cost.  Obstet Gynecol. 2001;  97 (6) 982-987
• 5 Turnbull D A, Wilkinson C, Gerard K et al.. Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women.  Lancet. 2004;  363 (9415) 1104-1109
• 6 Simon J, Gray A, Duley L. Magpie Trial Collaborative Group . Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial.  BJOG. 2006;  113 (2) 144-151
• 7 National High Blood Pressure Education Program Working Group Report on High Pressure in Pregnancy . National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy.  Am J Obstet Gynecol. 1990;  163 (5 Pt 1) 1691-1712
• 8 Diagnosis and management of pre-eclampsia and eclampsia. Armenian Medical Network. 2003. Available at: http://www.health.am/gyneco/more/preeclampsia_eclampsia
• 9 Freeman D J, Tham K, Brown E A, Rumley A, Lowe G D, Greer I A. Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia.  J Thromb Haemost. 2008;  6 (3) 421-427
• 10 VanWijk M J, Boer K, Berckmans R J et al.. Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents.  Thromb Haemost. 2002;  88 (3) 415-420
• 11 Kobayashi T, Tokunaga N, Sugimura M et al.. Coagulation/fibrinolysis disorder in patients with severe preeclampsia.  Semin Thromb Hemost. 1999;  25 (5) 451-454
• 12 Kruithof E K, Tran-Thang C, Gudinchet A et al.. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors.  Blood. 1987;  69 (2) 460-466
• 13 Estellés A, Gilabert J, Keeton M et al.. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation.  Blood. 1994;  84 (1) 143-150
• 14 Estellés A, Gilabert J, Aznar J, Loskutoff D J, Schleef R R. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia.  Blood. 1989;  74 (4) 1332-1338
• 15 Djelmis J, Kendić S, Buković D, Pfeifer D, Ivanisević M. The effect of coagulation parameters on the placental respiratory and nutritive function in women having chronic hypertension with superimposed preeclampsia.  Coll Antropol. 1997;  21 (1) 127-137
• 16 Bremme K, Blombäck M. Hemostatic abnormalities may predict chronic hypertension after preeclampsia.  Gynecol Obstet Invest. 1996;  41 (1) 20-26
• 17 Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset P M, Wisløff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia.  Acta Obstet Gynecol Scand. 1999;  78 (3) 191-197
• 18 Savelieva G M, Efimov V S, Grishin V L, Shalina R I, Kashezheva A Z. Blood coagulation changes in pregnant women at risk of developing preeclampsia.  Int J Gynaecol Obstet. 1995;  48 (1) 3-8
• 19 Kobayashi T, Sumimoto K, Tokunaga N et al.. Coagulation index to distinguish severe preeclampsia from normal pregnancy.  Semin Thromb Hemost. 2002;  28 (6) 495-500
• 20 Dusse L M, Carvalho M G, Getliffe K, Voegeli D, Cooper A J, Lwaleed B A. Increased circulating thrombomodulin levels in pre-eclampsia.  Clin Chim Acta. 2008;  387 (1–2) 168-171
• 21 Tanjung M T, Siddik H D, Hariman H, Koh S C. Coagulation and fibrinolysis in preeclampsia and neonates.  Clin Appl Thromb Hemost. 2005;  11 (4) 467-473
• 22 Vinnars M T, Wijnaendts L C, Westgren M, Bolte A C, Papadogiannakis N, Nasiell J. Severe preeclampsia with and without HELLP differ with regard to placental pathology.  Hypertension. 2008;  51 (5) 1295-1299
• 23 Øian P, Omsjø I, Maltau J M, Osterud B. Increased sensitivity to thromboplastin synthesis in blood monocytes from pre-eclamptic patients.  Br J Obstet Gynaecol. 1985;  92 (5) 511-517
• 24 Yamada N, Kido K, Hayashi S, Mukai M, Harbara H. An experimental model of toxemia of pregnancy in spontaneously hypertensive rats (SHR).  Int J Biol Res Pregnancy. 1981;  2 (2) 58-62
• 25 Brown M A. The physiology of pre-eclampsia.  Clin Exp Pharmacol Physiol. 1995;  22 (11) 781-791
• 26 Howie P W, Begg C B, Purdie D W, Prentice C R. Use of coagulation tests to predict the clinical progress of pre-eclampsia.  Lancet. 1976;  2 (7981) 323-325
• 27 Sandset P M, Hellgren M, Uvebrandt M, Bergström H. Extrinsic coagulation pathway inhibitor and heparin cofactor II during normal and hypertensive pregnancy.  Thromb Res. 1989;  55 (5) 665-670
• 28 Estellés A, Gilabert J, Grancha S et al.. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia.  Thromb Haemost. 1998;  79 (3) 500-508
• 29 Bellart J, Gilabert R, Anglès A et al.. Tissue factor levels and high ratio of fibrinopeptide A: D-dimer as a measure of endothelial procoagulant disorder in pre-eclampsia.  Br J Obstet Gynaecol. 1999;  106 (6) 594-597
• 30 Erez O, Romero R, Hoppensteadt D et al.. Tissue factor and its natural inhibitor in pre-eclampsia and SGA.  J Matern Fetal Neonatal Med. 2008;  21 (12) 855-869
• 31 Aharon A, Lanir N, Drugan A, Brenner B. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment.  J Thromb Haemost. 2005;  3 (10) 2355-2357
• 32 Abdel Gader A M, Al-Mishari A A, Awadalla S A, Buyuomi N M, Khashoggi T, Al-Hakeem M. Total and free tissue factor pathway inhibitor in pregnancy hypertension.  Int J Gynaecol Obstet. 2006;  95 (3) 248-253
• 33 Dusse L M, Carvalho M G, Getliffe K, Voegeli D, Cooper A J, Lwaleed B A. Total plasma tissue factor pathway inhibitor levels in pre-eclampsia.  Clin Chim Acta. 2008;  388 (1–2) 230-232
• 34 Hillman S, Chant I, Gu M, Rose P, Vatish M. Tissue pathway factor inhibitor (TFPI) activity is elevated in pregnant patients at 20 weeks gestation who subsequently develop preeclampsia.  Thromb Haemost. 2009;  101 (4) 778-780
• 35 Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia.  Br J Obstet Gynaecol. 1994;  101 (6) 488-492
• 36 Rousseau A, Favier R, Van Dreden P. Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: new and useful markers for pre-eclampsia?.  Eur J Obstet Gynecol Reprod Biol. 2009;  146 (1) 46-49
• 37 Villar J, Carroli G, Wojdyla D World Health Organization Antenatal Care Trial Research Group et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?.  Am J Obstet Gynecol. 2006;  194 (4) 921-931
• 38 Grisaru-Granovsky S, Halevy T, Eidelman A, Elstein D, Samueloff A. Hypertensive disorders of pregnancy and the small for gestational age neonate: not a simple relationship.  Am J Obstet Gynecol. 2007;  196 (4) 335, e1-e5
• 39 Chinni E, Colaizzo D, Tiscia G L et al.. Markers of haemostasis and angiogenesis in placentae from gestational vascular complications: impairment of mechanisms involved in maintaining intervillous blood flow.  Thromb Res. 2010;  125 (3) 267-271
• 40 Ogawa M, Yanoma S, Nagashima Y et al.. Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key.  Placenta. 2007;  28 (2-3) 224-232
• 41 Parry G C, Mackman N. Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain.  J Clin Invest. 2000;  105 (11) 1547-1554
• 42 Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta.  Semin Thromb Hemost. 2003;  29 (2) 175-184
• 43 Palmier M O, Hall L J, Reisch C M, Baldwin M K, Wilson A G, Wun T C. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits.  Thromb Haemost. 1992;  68 (1) 33-36
• 44 Donahue B S, Gailani D, Mast A E. Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass.  J Thromb Haemost. 2006;  4 (5) 1011-1016
• 45 Moran P, Lindheimer M D, Davison J M. The renal response to preeclampsia.  Semin Nephrol. 2004;  24 (6) 588-595
• 46 Morris R H, Vassalli P, Beller F K, McCluskey R T. Immunofluorescent studies of renal biopsies in the diagnosis of toxemia of pregnancy.  Obstet Gynecol. 1964;  24 32-46
• 47 Deng L, Bremme K, Hansson L O, Blombäck M. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia.  Obstet Gynecol. 1994;  84 (6) 941-945
• 48 Polliotti B M, Fry A G, Saller D N, Mooney R A, Cox C, Miller R K. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia.  Obstet Gynecol. 2003;  101 (6) 1266-1274
• 49 Powers R W, Roberts J M, Cooper K M et al.. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia.  Am J Obstet Gynecol. 2005;  193 (1) 185-191
• 50 Unal E R, Robinson C J, Johnson D D, Chang E Y. Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia.  Am J Obstet Gynecol. 2007;  197 (2) 211, e1-e4
• 51 Redman C W, Denson K W, Beilin L J, Bolton F G, Stirrat G M. Factor-VIII consumption in pre-eclampsia.  Lancet. 1977;  2 (8051) 1249-1252
• 52 Meade T W, Miller G J, Rosenberg R D. Characteristics associated with the risk of arterial thrombosis and the pre-thrombotic state. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, PA: WB Saunders; 1992: 79-97
• 53 Bremme K, Wramsby H, Andersson O, Wallin M, Blombäck M. Do lowered factor VII levels at extremely high endogenous oestradiol levels protect against thrombin formation?.  Blood Coagul Fibrinolysis. 1994;  5 (2) 205-210
• 54 Greer I A, Haddad N G, Dawes J, Johnstone F D, Calder A A. Neutrophil activation in pregnancy-induced hypertension.  Br J Obstet Gynaecol. 1989;  96 (8) 978-982
• 55 Cignetti M, Garzetti G G, Marchegiani F, Fabris N, Romanini C. Natural killer cells and Tac antigen in the hypertension of pregnancy.  Clin Exp Obstet Gynecol. 1990;  17 (1) 13-15